ken yamagiwa

Dr. ken yamagiwa

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
KYken yamagiwa
ken yamagiwa
JTJunichi Tsuchiya
Junichi Tsuchiya
KYKota Yokoyama
Kota Yokoyama
RWRyosuke Watanabe
Ryosuke Watanabe
KKKoichiro Kimura
Koichiro Kimura
UTUkihide Tateishi
Ukihide Tateishi
Deep learning (DL) image quality improvement has been studied for application to 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). It is unclear, however, whether DL can increase the quality of images obtained with semiconductor-based PET/CT scanners. This study aimed to compare the quality of semiconductor-based PET/CT scanner images obtained by DL-based technology and conventional OSEM image with Gaussian postfilter. For DL-based data processing implementation, we used Advanced Intelligent Clear-IQ Engine (AiCE, Canon Medical Systems, Tochigi, Japan) and for OSEM images, Gaussian postfilter of 3 mm FWHM is used. Thirty patients who underwent semiconductor-based PET/CT scanner imaging between May 6, 2021, and May 19, 2021, were enrolled. We compared AiCE images and OSEM images and scored them for delineation, image noise, and overall image quality. We also measured standardized uptake values (SUVs) in tumors and healthy tissues and compared them between AiCE and OSEM. AiCE images scored significantly higher than OSEM images for delineation, image noise, and overall image quality. The Fleiss kappa value for the interobserver agreement was 0.57. Among the 21 SUV measurements in healthy organs, 11 (52.4%) measurements were significantly different between AiCE and OSEM images. More pathological lesions were detected in AiCE images as compared with OSEM images, with AiCE images showing higher SUVs for pathological lesions than OSEM images. AiCE can improve the quality of images acquired with semiconductor-based PET/CT scanners, including the noise level, contrast, and tumor detection capability.

20 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMio Mori
Mio Mori
TFTomoyuki Fujioka
Tomoyuki Fujioka
MHMayumi Hara
Mayumi Hara
LKLeona Katsuta
Leona Katsuta
YYYuka Yashima
Yuka Yashima
UTUkihide Tateishi
Ukihide Tateishi
We investigated whether 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography images restored via deep learning (DL) improved image quality and affected axillary lymph node (ALN) metastasis diagnosis in patients with breast cancer. Using a five-point scale, two readers compared the image quality of DL-PET and conventional PET (cPET) in 53 consecutive patients from September 2020 to October 2021. Visually analyzed ipsilateral ALNs were rated on a three-point scale. The standard uptake values SUVmax and SUVpeak were calculated for breast cancer regions of interest. For “depiction of primary lesion”, reader 2 scored DL-PET significantly higher than cPET. For “noise”, “clarity of mammary gland”, and “overall image quality”, both readers scored DL-PET significantly higher than cPET. The SUVmax and SUVpeak for primary lesions and normal breasts were significantly higher in DL-PET than in cPET (p < 0.001). Considering the ALN metastasis scores 1 and 2 as negative and 3 as positive, the McNemar test revealed no significant difference between cPET and DL-PET scores for either reader (p = 0.250, 0.625). DL-PET improved visual image quality for breast cancer compared with cPET. SUVmax and SUVpeak were significantly higher in DL-PET than in cPET. DL-PET and cPET exhibited comparable diagnostic abilities for ALN metastasis.

31 March 2026 in Japanese Journal of Radiology
Verified
Journal Article
Open access
PDF file
YKYusuke Kawasaki
Yusuke Kawasaki
MNMaika Nakajima
Maika Nakajima
KYKota Yokoyama
Kota Yokoyama
EYEmi Yamaga
Emi Yamaga
MKMakoto Kato
Makoto Kato
UTUkihide Tateishi
Ukihide Tateishi
Purpose: This study investigated whether contrast enhanced whole-body photon-counting detector (PCD)-CT performed for staging in the prone position can provide breast lesion conspicuity comparable to dynamic contrast-enhanced T1-weighted imaging (DCE-T1WI). Methods: This single-center, retrospective diagnostic feasibility study included 22 women with surgically confirmed primary breast cancer who underwent preoperative prone PCD-CT and DCE-MRI. Then, 40- and 70-keV virtual monoenergetic image (VMI) from a single arterial-phase PCD-CT acquisition were reconstructed. Three readers independently evaluated 40- and 70-keV VMI and DCE-T1WI. The primary endpoint was lesion conspicuity. The secondary endpoints included, size error, detection rate, background parenchymal enhancement (BPE), subjective noise, and reading time. Results: Lesion conspicuity was highest on 40-keV VMI, which outperformed 70-keV VMI and DCE-T1WI. Absolute size error was numerically larger for 40-keV VMI than for DCE-T1WI, but this difference was not statistically significant. Directional error indicated that 40-keV VMI significantly underestimated lesion size relative to DCE-T1WI. Detection rates showed an overall difference among modalities, but pairwise differences were not statistically significant. Further, 40-keV VMI had a higher BPE and a greater perceived noise than 70-keV VMI, and it required a longer reading time than DCE-T1WI. The radiation dose did not differ between VMI energy levels as both were reconstructed from the same acquisition. Conclusion: Arterial-phase 40-keV VMIs from prone PCD-CT demonstrated the highest lesion conspicuity and showed better detection capability than 70-keV VMI. In addition, their performance was comparable to or superior to DCE-T1WI. This finding was achieved despite trade-offs in increased noise, BPE and size underestimation. Thus, 40-keV VMI may serve as a useful complementary modality for local breast assessment and may be considered a potential alternative for lesion localization when MRI is not feasible, despite potential underestimation of lesion extent.

18 August 2025 in Cancer Genetics
Verified
Journal Article
Open access
HNHaruko Nakagawa
Haruko Nakagawa
SASatoru Aoyama
Satoru Aoyama
JYJunko Yokobori
Junko Yokobori
HFHaruhiko Furusawa
Haruhiko Furusawa
TMTakahiro Mitsumura
Takahiro Mitsumura
SISadakatsu Ikeda
Sadakatsu Ikeda
Fumarate hydratase (FH) is a tumor suppressor gene implicated in the tumorigenesis of several cancers, including renal cell carcinoma. However, FH mutations are uncommon in lung adenocarcinoma, and frameshift deletions are exceedingly rare. Here, we report a novel FH frameshift mutation (G97fs*3) in a 67-year-old woman with lung adenocarcinoma. The mutation was detected through comprehensive genomic profiling. It occurs within the catalytic domain of FH and has not been previously reported in this cancer type. A literature review revealed that FH mutations are oncogenic in hereditary leiomyomatosis and renal cell cancer, suggesting that the frameshift mutation could also serve as a driver mutation in this case. This report highlights the utility of comprehensive genomic profiling in identifying clinically relevant mutations and demonstrates the potential of leveraging such insights for precision oncology. FH alterations, such as the one described, could represent potential therapeutic targets from molecular perspectives.